Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died, the Wall Street Journal reported on Tuesday.
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthcare which was planning a generic rival.
Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. business under drug-pricing policies introduced by the Trump administration, a study showed on Thursday.
Stock futures are rising after three straight days of declines for major indexes; chip stocks are leading the rebound as volatility in the AI trade persists; several big-name companies reported earnings this morning ahead of Big Tech results tomorrow; Nebius shares are surging on news Nvidia as increased its stake in the Dutch AI infrastructure company; and SpaceX shares are rising after closin...
Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.
Novartis chief executive officer Vas Narasimhan said on Tuesday he plans to stick around for the Swiss drugmaker's next phase of growth, ahead of a series of high-stakes trial data expected for the company in the second half of the year.